Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

822 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL Jr, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. Sharma M, et al. Among authors: parmar s. Cancer. 2012 May 1;118(9):2507-15. doi: 10.1002/cncr.26517. Epub 2011 Sep 1. Cancer. 2012. PMID: 21887685 Free PMC article. Clinical Trial.
Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease.
Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Parmar S, et al. Blood. 2009 Oct 1;114(14):2884-7. doi: 10.1182/blood-2009-05-223172. Epub 2009 Aug 4. Blood. 2009. PMID: 19654407 Free PMC article.
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.
Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ. Parmar S, et al. J Clin Oncol. 2011 Jan 20;29(3):294-302. doi: 10.1200/JCO.2010.30.6357. Epub 2010 Dec 13. J Clin Oncol. 2011. PMID: 21149654 Free PMC article. Clinical Trial.
Umbilical cord blood transplantation.
Bashir Q, Robinson SN, de Lima MJ, Parmar S, Shpall E. Bashir Q, et al. Among authors: parmar s. Clin Adv Hematol Oncol. 2010 Nov;8(11):786-801. Clin Adv Hematol Oncol. 2010. PMID: 21326157
Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
Yang H, Robinson SN, Nieto Y, Jones RJ, Gocke CD, Lu J, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, McMannis JD, Ng J, Thomas MW, Shah N, Andersson BS, Parmar S, Shpall EJ. Yang H, et al. Among authors: parmar s. Cancer Res. 2011 Jul 15;71(14):5040-9. doi: 10.1158/0008-5472.CAN-11-0842. Epub 2011 Jun 6. Cancer Res. 2011. PMID: 21646477
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma.
Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Bashir Q, et al. Among authors: parmar s. Leuk Lymphoma. 2012 Jan;53(1):118-22. doi: 10.3109/10428194.2011.606942. Epub 2011 Aug 24. Leuk Lymphoma. 2012. PMID: 21780997
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Bashir Q, et al. Among authors: parmar s. Am J Hematol. 2012 Mar;87(3):272-6. doi: 10.1002/ajh.22273. Epub 2012 Jan 9. Am J Hematol. 2012. PMID: 22231283 Free PMC article.
Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant.
Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Beitinjaneh AM, et al. Among authors: parmar s. Leuk Lymphoma. 2012 Aug;53(8):1525-9. doi: 10.3109/10428194.2012.656635. Epub 2012 Mar 1. Leuk Lymphoma. 2012. PMID: 22242817
822 results